TruScreen Group (TRU) H2 2025 earnings summary

Executive summary

• China accounted for over 85% of global sales, exceeding budget and targeted for further expansion in six key provinces.

• Strategic alliances and new distributor appointments in India, Indonesia, and Vietnam position the company for growth in FY2026.

• FY2025 sales were $1.7m, down from $2.1m year-over-year, mainly due to delayed rollouts and product registrations.

• Clinical trials and independent studies, including WHO validation, confirm suitability for large-scale screening in emerging markets.

Financial highlights

• FY2025 product sales reached $1.7m, compared to $2.1m in FY2024.

• Gross margin was 30.1%, down from 32.7% year-over-year, due to sales mix and program delays.

• Operating cash outflow was $2.3m (FY2024: $2.0m); year-end cash balance was $0.4m (FY2024: $2.7m).

• Overhead expenses reduced to $3.1m from $3.24m year-over-year.

• Net loss for the year was $2.2m, compared to $2.0m in FY2024.

Outlook and guidance

• FY2026 sales are projected to exceed $2.8m, a 64% year-over-year increase, driven by new market entries and resumed programs.

• Growth expected from China, Vietnam, India, Indonesia, Zimbabwe, and DaltonBio HPV test kit sales.

• China sales forecasted to rise 15% in FY2026.